Prestige Consumer Healthcare Q1 FY2027: Revenue Climbs 6.5% on Breathe Right, but Integration Costs Weigh on Margins

summarizeSummary

Prestige Consumer Healthcare's Q1 FY2027 results reveal the early financial impact of the $1.045B Breathe Right acquisition: revenue rose 6.5%, but net income dropped 38.5% due to acquisition costs and margin compression. Total debt surged to $2.0B. After the quarter, the company completed the $150M LaCorium Health acquisition and a $400M debt refinancing.

check_boxKey Events · Earnings and Guidance · PBH

• Revenue Up 6.5% on Breathe Right

  Driven by the Breathe Right acquisition and growth in gastrointestinal and dermatological categories, total revenues reached $265.7 million, though women's health saw declines.

• Net Income Plunges 38.5%

  Weighed down by $10.6 million in acquisition costs and $14.2 million in inventory step-up amortization, net income fell to $29.2 million ($0.61 per share) from $47.5 million ($0.95 per share) a year ago.

• Gross Margin Compressed to 51.3%

  Gross margin declined 490 basis points year-over-year to 51.3%, primarily due to costs associated with optimizing the Pillar5 facility and the Breathe Right inventory fair value step-up.

• Debt More Than Doubles to $2.0B

  Following the $1.045 billion term loan to fund the Breathe Right acquisition, total debt increased to $2.045 billion from $1.0 billion at March 31, 2026. The ABL facility was expanded to $225 million.

auto_awesomeAnalysis · PBH · Life Sciences

The first quarter of fiscal 2027 marks the initial impact of the transformative $1.045 billion Breathe Right acquisition, which closed mid-quarter. Revenue grew 6.5% to $265.7 million, yet gross margin contracted sharply to 51.3% from 56.2% a year ago, driven by $14.2 million in inventory step-up amortization and costs to optimize the acquired Pillar5 manufacturing facility. General and administrative expenses surged 52% to $43.3 million, largely due to $10.6 million in acquisition-related costs. As a result, net income fell 38.5% to $29.2 million, and diluted EPS dropped to $0.61 from $0.95. The balance sheet has been fundamentally reshaped: total debt more than doubled to $2.0 billion, and goodwill and intangibles ballooned by over $1 billion. The company also disclosed the completion of the $150 million LaCorium Health acquisition on July 1 and a $400 million senior notes offering to refinance higher-cost debt. While the acquisitions position Prestige for long-term growth in wellness and international markets, the near-term earnings drag and elevated leverage are significant. The filing also highlights ongoing supply chain disruptions in eye care products, which continue to pressure sales. Investors will focus on the pace of integration, deleveraging, and margin recovery.